Table 3.
Prevalences of CMRFs and metabolic syndrome based on BMI category and sex
| CMRFs | BMI category | All |
Boys |
Girls |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Participants | Prevalence % (95% CI) | P-value | Participants | Prevalence % (95% CI) | P-value | Participants | Prevalence % (95% CI) | P-value | ||
| TC ≥ 200 mg/dL | NW | 6,874 | 6.27 (5.65–6.95) | <0.001 | 3,583 | 4.21 (3.53–5.00) | <0.001 | 3,291 | 8.56 (7.54–9.70) | <0.001 |
| OW | 843 | 10.83 (8.69–13.42) | 473 | 12.24 (9.17–16.15) | 370 | 9.07 (6.39–12.73) | ||||
| Class I OB | 649 | 14.48 (11.46–18.13) | 362 | 10.86 (7.52–15.45) | 287 | 18.50 (13.83–24.30) | ||||
| Class II/III OB | 183 | 18.66 (12.79–26.41) | 121 | 19.54 (12.65–28.94) | 62 | 16.69 (7.58–33.04) | ||||
| Total | 8,549 | 7.64 (7.00–8.33) | 4,539 | 5.98 (5.22–6.85) | 4,010 | 9.52 (8.53–10.62) | ||||
| HDL-C<40 mg/dL | NW | 6,872 | 9.54 (8.72–10.43) | <0.001 | 3,582 | 11.76 (10.61–13.02) | <0.001 | 3,290 | 7.08 (6.10–8.21) | <0.001 |
| OW | 843 | 19.29 (16.37–22.59) | 473 | 25.00 (20.65–29.92) | 370 | 12.18 (8.97–16.33) | ||||
| Class I OB | 649 | 26.13 (22.31–30.34 | 362 | 30.75 (25.47–36.58) | 287 | 20.98 (16.11–26.85) | ||||
| Class II/III OB | 183 | 41.44 (33.54–49.81) | 121 | 38.60 (29.35–48.75) | 62 | 47.63 (33.68–61.97) | ||||
| Total | 8,547 | 12.52 (11.68–13.42) | 4,538 | 15.36 (14.18–16.62) | 4,009 | 9.30 (8.26–10.45) | ||||
| LDL-C≥130 mg/ dL | NW | 6,872 | 4.53 (4.00–5.12) | <0.001 | 3,582 | 3.19 (2.62–3.89) | <0.001 | 3,290 | 6.01 (5.15–7.00) | <0.001 |
| OW | 843 | 10.18 (8.09–12.74) | 473 | 10.89 (8.00–14.67) | 370 | 9.29 (6.69–12.78) | ||||
| Class I OB | 649 | 12.87 (10.03–16.35) | 421 | 9.02 (6.04–13.27) | 287 | 17.15 (12.60–22.92) | ||||
| Class II/III OB | 183 | 20.32 (14.20–28.21) | 62 | 21.59 (14.46–30.97) | 62 | 17.55 (8.22–33.61) | ||||
| Total | 8,547 | 6.09 (5.52–6.72) | 4,538 | 4.97 (4.28–5.76) | 4,009 | 7.37 (6.49–8.36) | ||||
| Triglycerides≥150 mg/dL | NW | 6,874 | 6.10 (5.44–6.84) | <0.001 | 3,583 | 5.82 (4.95–6.82) | <0.001 | 3,291 | 6.42 (5.53–7.45) | <0.001 |
| OW | 843 | 15.48 (12.81–18.58) | 473 | 19.00 (15.01–23.74) | 370 | 11.10 (8.07–15.09) | ||||
| Class I OB | 649 | 21.20 (17.86–24.98) | 362 | 19.16 (15.06–24.07) | 287 | 23.48 (18.48–29.34) | ||||
| Class II/III OB | 183 | 27.80 (20.80–36.09) | 121 | 28.66 (20.19–38.96) | 62 | 25.92 (14.99–40.99) | ||||
| Total | 8,549 | 8.69 (7.97–9.46) | 4,539 | 8.85 (7.88–9.92) | 4,010 | 8.50 (7.55–9.56) | ||||
| Non-HDL-C≥145 mg/dL | NW | 6,872 | 6.04 (5.43–6.72) | <0.001 | 3,582 | 4.45 (3.77–5.25) | <0.001 | 3,290 | 7.80 (6.80–8.91) | <0.001 |
| OW | 843 | 13.92 (11.47–16.80) | 473 | 15.93 (12.41–20.23) | 370 | 11.42 (8.43–15.28) | ||||
| Class I OB | 649 | 20.42 (17.02–24.30) | 421 | 16.70 (12.74–21.58) | 287 | 24.56 (19.33–30.68) | ||||
| Class II/III OB | 183 | 26.45 (19.70–34.51) | 62 | 26.74 (18.77–36.57) | 62 | 25.81 (14.69–41.29) | ||||
| Total | 8,547 | 8.39 (7.72–9.12) | 4,538 | 7.22 (6.40–8.14) | 4,009 | 9.73 (8.71–10.86) | ||||
| BP≥95th percentile for sex, age, and height | NW | 8,020 | 4.88 (4.35–5.47) | <0.001 | 4,161 | 4.90 (4.19–5.73) | <0.001 | 3,859 | 4.85 (4.11–5.73) | <0.001 |
| OW | 997 | 10.55 (8.35–13.25) | 562 | 12.26 (9.14–16.25) | 435 | 8.45 (5.83–12.09) | ||||
| Class I OB | 756 | 13.80 (11.20–16.87) | 425 | 14.31 (10.87–18.62) | 331 | 13.19 (9.44–18.14) | ||||
| Class II/III OB | 211 | 29.68 (23.11–37.20) | 141 | 28.19 (20.46–37.47) | 70 | 33.07 (21.79–46.71) | ||||
| Total | 9,984 | 6.71 (6.13–7.34) | 5,289 | 7.11 (6.29–8.02) | 4,695 | 6.26 (5.47–7.15) | ||||
| Fasting glucose ≥100 mg/dL | NW | 6,847 | 6.81 (6.10–7.59) | <0.001 | 3,568 | 8.41 (7.36–9.60) | 0.030 | 3,279 | 5.04 (4.27–5.94) | <0.001 |
| OW | 839 | 9.69 (7.69–12.14) | 471 | 11.81 (8.90–15.51) | 368 | 7.05 (4.75–10.33) | ||||
| Class I OB | 649 | 12.24 (9.49–15.64) | 361 | 12.93 (7.93–15.45) | 288 | 11.47 (7.86–16.45) | ||||
| Class II/III OB | 182 | 13.66 (8.67–20.87) | 121 | 8.98 (4.85–16.04) | 61 | 24.06 (12.79–40.64) | ||||
| Total | 8,517 | 7.67 (6.98–8.42) | 4,521 | 9.11 (8.14–10.19) | 3,996 | 6.04 (5.23–6.95) | ||||
| HbA1c ≥5.7% | NW | 4,128 | 15.47 (14.12–16.93) | <0.001 | 2,157 | 16.45 (14.62–18.45) | 0.025 | 1,971 | 14.40 (12.65–16.33) | <0.001 |
| OW | 495 | 17.26 (13.84–21.30) | 276 | 19.64 (14.86–25.51) | 219 | 14.44 (9.97–20.47) | ||||
| Class I OB | 429 | 21.66 (17.50–26.49) | 234 | 19.79 (14.65–26.19) | 195 | 23.62 (17.38–31.26) | ||||
| Class II/III OB | 124 | 32.23 (23.73–42.09) | 81 | 28.80 (19.14–40.87) | 3,843 | 39.56 (24.45–56.96) | ||||
| Total | 5,176 | 16.62 (15.33–17.98) | 2,748 | 17.45 (15.74–19.31) | 2,428 | 15.68 (14.03–17.48) | ||||
| MetS (IDF) | NW | 6,824 | 0.05 (0.02–0.14) | <0.001 | 3,557 | 0 (0–0) | <0.001 | 3,267 | 0.11 (0.04–0.29) | <0.001 |
| OW | 836 | 2.63 (1.51–4.56) | 471 | 2.06 (0.75–5.49) | 365 | 3.35 (1.80–6.14) | ||||
| Class I OB | 647 | 12.48 (9.89–15.63) | 361 | 10.98 (7.98–14.93) | 286 | 14.15 (10.09–19.50) | ||||
| Class II/III OB | 181 | 30.89 (23.64–39.22) | 120 | 28.16 (19.84–38.29) | 61 | 36.92 (23.88–52.20) | ||||
| Total | 8,488 | 2.01 (1.68–2.40) | 4,509 | 1.93 (1.50–2.49) | 3,979 | 2.10 (1.63–2.70) | ||||
| MetS (modified NCEP-ATP III) | NW | 6,824 | 0.63 (0.44–0.88) | <0.001 | 3,557 | 0.53 (0.34–0.85) | <0.001 | 3,267 | 0.72 (0.44–1.17) | <0.001 |
| OW | 836 | 5.68 (3.99–8.01) | 471 | 6.57 (4.18–10.19) | 365 | 4.55 (2.53–8.07) | ||||
| Class I OB | 647 | 18.96 (15.66–22.76) | 361 | 19.91 (15.66–24.98) | 286 | 17.90 (13.29–23.68) | ||||
| Class II/III OB | 181 | 42.70 (34.53–51.29) | 120 | 42.31 (32.61–52.65) | 61 | 43.55 (30.05–58.07) | ||||
| Total | 8,488 | 3.55 (3.01–4.06) | 4,509 | 3.93 (3.32–4.65) | 3,979 | 3.11 (2.51–3.86) | ||||
CMRF, cardiometabolic risk factor; BMI, body mass index; CI, confidence interval; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BP, blood pressure; HbA1c, glycated hemoglobin; MetS, metabolic syndrome; IDF, International Diabetes Federation; NCEP-ATP III, National Cholesterol Education Program-Adult Treatment Panel III; NW, normal weight; OW, overweight; OB, obesity.